Abcam, ab313378, Anti-FKBP12 antibody [EPR27367-59]

Size: 20µL / 100µL / 1mL
Knockout Tested Rabbit Recombinant Monoclonal FKBP12 antibody. Suitable for WB and reacts with Human, Mouse, Rat, Transfected cell lysate - Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27367-59,
Isotype:IgG,
Carrier free:No,
Reacts with:Human, Mouse, Rat,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody recognizes both FKBP12/FKBP1A and FKBP12.6/FKBP1B.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FKBP12 also known as FKBP-12 or FKBP12 protein is a small protein with a molecular weight of approximately 12 kDa. It belongs to the family of immunophilins and acts as a peptidyl-prolyl cis-trans isomerase (PPIase) facilitating the folding of proteins by catalyzing the isomerization of proline residues in polypeptides. The FKBP12 protein is expressed in various tissues throughout the body including the brain heart and skeletal muscles. It plays a mechanical role in binding certain macrolide antibiotics such as FK506 (tacrolimus) influencing their biological effects by altering protein conformation.
Biological function summary
FKBP12 is significant in cellular mechanisms beyond protein folding. It interacts with and forms complexes with other proteins such as ryanodine receptors and transforming growth factor-beta (TGF-β) receptors impacting calcium signaling and cell growth. FKBP12's interaction with FK506 has been extensively studied because it forms a complex that inhibits calcineurin ultimately leading to immunosuppressive effects. This property of FKBP12 makes it important for modulating the immune response and has importance in transplant medicine.
Pathways
FKBP12 is actively involved in calcium signaling and TGF-β signaling pathways. FKBP12 influences these pathways by binding to ryanodine receptors affecting calcium release from intracellular stores and also modulating the function of TGF-β receptors impacting cellular growth and proliferation processes. It is associated with proteins such as calcineurin and Smad proteins in these pathways maintaining cellular homeostasis and regulating immune and inflammatory responses.
FKBP12 plays a role in immunological and proliferative diseases. It is implicated in autoimmune disorders due to its interaction with FK506 leading to the suppression of unwanted immune responses. FKBP12 is also linked to cardiac hypertrophy as its modulation of calcium release through ryanodine receptors can affect heart muscle function. The protein interacts with calcineurin in these contexts contributing to pathological processes in these diseases. Researchers target FKBP12 with ELISA and other assays to investigate its involvement in these disorders and assess therapeutic interventions.